Literature DB >> 24105326

Frequency of KRAS mutations in adult Korean patients with acute myeloid leukemia.

Mi-Jung Park1, Soon-Ho Park, Pil-Whan Park, Yiel-Hea Seo, Kyung-Hee Kim, Ji-Hun Jeong, Moon Jin Kim, Jeong-Yeal Ahn, Jae Hoon Lee, Jinny Park, Junshik Hong.   

Abstract

Mutation of KRAS genes occurs with a frequency of 0.5-32 % in AML. In the present study, mutations of KRAS codon 12, 13, and 61 were detected by pyrosequencing and direct sequencing in AML. Seven KRAS mutations (7/123, 5.7 %) were detected. The most common mutation was a G-to-A transition in the second base of KRAS codon 13. No mutations were detected in KRAS codon 61. Combinations of KRAS and FLT3 mutation were not found in the same patient. There was no statistically significant difference between patients with KRAS mutations and patients with wild-type KRAS in terms of sex, age, CBC at diagnosis, CD34 positivity, MPO positivity, FLT3 mutation, karyotype, progression-free survival, and overall survival, although this may be attributable to the small sample size. To our knowledge, this is the first report of the detection of KRAS mutation in Asian AML patients using pyrosequencing and direct sequencing. These two methods showed identical efficiencies in their ability to detect KRAS mutations in 84 patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24105326     DOI: 10.1007/s12185-013-1446-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  36 in total

1.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Liying Yan; Mami Cantor; Chungdak Namgyal; Mari Mino-Kenudson; Gregory Y Lauwers; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

2.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

Authors:  H Kiyoi; T Naoe; Y Nakano; S Yokota; S Minami; S Miyawaki; N Asou; K Kuriyama; I Jinnai; C Shimazaki; H Akiyama; K Saito; H Oh; T Motoji; E Omoto; H Saito; R Ohno; R Ueda
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

3.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

4.  Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia.

Authors:  Markus Ritter; Theo Daniel Kim; Petra Lisske; Christian Thiede; Markus Schaich; Andreas Neubauer
Journal:  Haematologica       Date:  2004-11       Impact factor: 9.941

5.  N-ras mutations in 43 Chinese cases of acute myeloid leukemia.

Authors:  W Guo; B Tang; S Xu; Y Yao; D Ye
Journal:  Chin Med J (Engl)       Date:  1998-04       Impact factor: 2.628

6.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 7.  Molecular targets in acute myelogenous leukemia.

Authors:  Derek L Stirewalt; Soheil Meshinchi; Jerald P Radich
Journal:  Blood Rev       Date:  2003-03       Impact factor: 8.250

8.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia.

Authors:  A Neubauer; R K Dodge; S L George; F R Davey; R T Silver; C A Schiffer; R J Mayer; E D Ball; D Wurster-Hill; C D Bloomfield
Journal:  Blood       Date:  1994-03-15       Impact factor: 22.113

9.  K-ras mutation detection in colorectal cancer using the Pyrosequencing technique.

Authors:  Angela Poehlmann; Doerthe Kuester; Frank Meyer; Hans Lippert; Albert Roessner; Regine Schneider-Stock
Journal:  Pathol Res Pract       Date:  2007-07-12       Impact factor: 3.250

10.  KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.

Authors:  Magnus Sundström; Karolina Edlund; Monica Lindell; Bengt Glimelius; Helgi Birgisson; Patrick Micke; Johan Botling
Journal:  BMC Cancer       Date:  2010-12-01       Impact factor: 4.430

View more
  3 in total

1.  Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.

Authors:  Xiaofei Zhou; Sharon Friedlander; Erik Kupperman; Farhad Sedarati; Shingo Kuroda; Zhaowei Hua; Ying Yuan; Yuka Yamamoto; Douglas V Faller; Kazue Haikawa; Katsuhiko Nakai; Sharon Bowen; Yi Dai; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-02-02       Impact factor: 4.689

2.  Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.

Authors:  Ke Xu; Dongkyoo Park; Andrew T Magis; Jun Zhang; Wei Zhou; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Xingming Deng
Journal:  Mol Cancer       Date:  2019-04-10       Impact factor: 27.401

3.  Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations.

Authors:  Afia Muhammad Akram; Asma Chaudhary; Humera Kausar; Fayez Althobaiti; Afshan Syed Abbas; Zawar Hussain; Naz Fatima; Erum Zafar; Wajiha Asif; Umair Afzal; Zoufishan Yousaf; Amjad Zafar; Steve M Harakeh; Samina Qamer
Journal:  Saudi J Biol Sci       Date:  2021-05-06       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.